Sinopharm Group Co L (SHTDF) 4.3700 $SHTDF
Provectus Biopharmaceuticals Extends for Additional 60 Days Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm a-Think Pharmaceutical Co., Ltd
Business Wire - Mon May 18, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT
VCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"
, today announced that it had extended for an additional 60 days its Memorandum of Understanding with with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI" , the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK" , the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group. The extension was the only change to the agreement, and the MOU is now in force through July 15, 2015.
PVCT: 0.51 (+0.01)
Week In Review: China's Innovent Raises $100 Million For Biologics Portfolio
ChinaBio Today - at Seeking Alpha - Sun Jan 25, 7:04AM CST
Deals and Financings Innovent Biologics of Suzhou announced a significant $100 million C round funding, which the company will use to advance its portfolio of eight biologic drug candidates. Founded in 2011, Innovent already has filed four IND...
CTLT: 28.96 (unch), PKI: 51.53 (+0.51)
Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd
Business Wire - Fri Nov 14, 5:00AM CST
Provectus Biopharmaceuticals, Inc. (NYSE MKT VCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus" , announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI" , the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK" , the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term.
PVCT: 0.51 (+0.01)
Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders
PR Newswire - Wed Oct 22, 6:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors reducing the potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
PVCT: 0.51 (+0.01)
Global and Chinese Chemical Reagent Industry Report 2014-2017
M2 - Tue Sep 30, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sjcjmv/global_and) has announced the addition of the "Global and Chinese Chemical Reagent Industry Report, 2014-2017" report to their offering. Chemical reagent, purified from industrial chemicals, serves chiefly scientific experiment and detection analysis, and finds massive application in electronic information, medicine, food, aerospace and military industry manufacturing. In 2013, global chemical reagent market was worth about USD 13.6 billion, with market demand concentrated in United States, Europe and Japan. There are a large variety of chemical reagents, totaling above 250,000 around the world. American Sigma-Aldrich is the company that produces the most varieties of chemical reagents, up to approximate 230,000. Global chemical reagent industry characterizes a fairly high concentration, and American Sigma-Aldrich and German Merck Group, as industry leaders, took up a combined 30% or so market share globally in 2013. China chemical reagent industry has developed quickly, achieving a CAGR of 15.9% as concerns market size during 2007-2013, and making up 19.2% of global market size. Chemical reagent can be divided into general reagent and high-purity reagent, with the latter accounting for about 26% of total market size in China in 2013. High-purity chemical reagent is mainly used in semiconductor industry, and is the product that enjoys the fastest growth rate and has the highest technical content and added value. With the rapid development of China's electronic information, biotechnology, national defense, military industry and other industries, the demand for high purity reagent will keep a roughly 15% growth rate over the next couple years. In 2013, there were more than 400 chemical reagent producers with production licenses in China, most of which focused on low-end products, resulting in fierce competition in the low-end market; by contrast, the high-end market is dominated by transnational companies, such as German Merck Group and American Sigma-Aldrich, which held a combined 16.9% market share in China in 2013. In recent years, concentration of China chemical reagent industry has been improving gradually, mainly reflected by rapid development of large chemical reagent companies. Moreover, China-made chemical reagents are advancing from the low-end to the middle and high-end, with some imported products having been substituted with domestic ones. Typical domestic companies include Xilong Chemical Co., Ltd. and Sinopharm Chemical Reagent Co., Ltd., together occupying 13.2% of the Chinese market in 2013. Key Topics Covered: 1. Overview of Chemical Reagent 2. Chemical Reagent Market 3. Chinese Chemical Reagent Market 4. Foreign Companies 5. Chinese Companies 6. Summary and Forecast Companies Mentioned - Anhui Fulltime Specialized Solvent & Reagent - Danaher - Guangdong Guanghua Sci-Tech - Jianghua Microelectronics Materials - Jiangyin Chemical Reagent Factory - Johnson Matthey - Merck Group - Sigma-Aldrich - Sinopharm Group - Suzhou Crystal Clear Chemical - Suzhou JIMCEL Electronic New Material - TCI - Thermo Fisher - Wako - Xilong Chemical For more information visit http://www.researchandmarkets.com/research/sjcjmv/global_and
MRK: 57.95 (+0.57), DHR: 86.65 (+0.91)
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
BSPM: 1.01 (+0.03), BAX: 37.61 (+0.59), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), SVA: 5.26 (+0.02), SNY: 51.49 (+2.71), CPHI: 0.28 (-0.01)
Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, and Sinopharm A-THINK Pharmaceutical Co., Ltd.
Business Wire - Mon Aug 18, 8:19AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus" , announced today that it entered into a Memorandum of Understanding ("MOU" with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI" , the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK" , the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.
PVCT: 0.51 (+0.01)
Provectus Biopharmaceuticals Extends for Additional 60 Days Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm a-Think Pharmaceutical Co., Ltd
Business Wire - Mon May 18, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT
VCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company" , today announced that it had extended for an additional 60 days its Memorandum of Understanding with with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI" , the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK" , the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group. The extension was the only change to the agreement, and the MOU is now in force through July 15, 2015. PVCT: 0.51 (+0.01)
Week In Review: China's Innovent Raises $100 Million For Biologics Portfolio
ChinaBio Today - at Seeking Alpha - Sun Jan 25, 7:04AM CST
Deals and Financings Innovent Biologics of Suzhou announced a significant $100 million C round funding, which the company will use to advance its portfolio of eight biologic drug candidates. Founded in 2011, Innovent already has filed four IND...
CTLT: 28.96 (unch), PKI: 51.53 (+0.51)
Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd
Business Wire - Fri Nov 14, 5:00AM CST
Provectus Biopharmaceuticals, Inc. (NYSE MKT
VCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus" , announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI" , the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK" , the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term. PVCT: 0.51 (+0.01)
Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders
PR Newswire - Wed Oct 22, 6:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors reducing the potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
PVCT: 0.51 (+0.01)
Global and Chinese Chemical Reagent Industry Report 2014-2017
M2 - Tue Sep 30, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sjcjmv/global_and) has announced the addition of the "Global and Chinese Chemical Reagent Industry Report, 2014-2017" report to their offering. Chemical reagent, purified from industrial chemicals, serves chiefly scientific experiment and detection analysis, and finds massive application in electronic information, medicine, food, aerospace and military industry manufacturing. In 2013, global chemical reagent market was worth about USD 13.6 billion, with market demand concentrated in United States, Europe and Japan. There are a large variety of chemical reagents, totaling above 250,000 around the world. American Sigma-Aldrich is the company that produces the most varieties of chemical reagents, up to approximate 230,000. Global chemical reagent industry characterizes a fairly high concentration, and American Sigma-Aldrich and German Merck Group, as industry leaders, took up a combined 30% or so market share globally in 2013. China chemical reagent industry has developed quickly, achieving a CAGR of 15.9% as concerns market size during 2007-2013, and making up 19.2% of global market size. Chemical reagent can be divided into general reagent and high-purity reagent, with the latter accounting for about 26% of total market size in China in 2013. High-purity chemical reagent is mainly used in semiconductor industry, and is the product that enjoys the fastest growth rate and has the highest technical content and added value. With the rapid development of China's electronic information, biotechnology, national defense, military industry and other industries, the demand for high purity reagent will keep a roughly 15% growth rate over the next couple years. In 2013, there were more than 400 chemical reagent producers with production licenses in China, most of which focused on low-end products, resulting in fierce competition in the low-end market; by contrast, the high-end market is dominated by transnational companies, such as German Merck Group and American Sigma-Aldrich, which held a combined 16.9% market share in China in 2013. In recent years, concentration of China chemical reagent industry has been improving gradually, mainly reflected by rapid development of large chemical reagent companies. Moreover, China-made chemical reagents are advancing from the low-end to the middle and high-end, with some imported products having been substituted with domestic ones. Typical domestic companies include Xilong Chemical Co., Ltd. and Sinopharm Chemical Reagent Co., Ltd., together occupying 13.2% of the Chinese market in 2013. Key Topics Covered: 1. Overview of Chemical Reagent 2. Chemical Reagent Market 3. Chinese Chemical Reagent Market 4. Foreign Companies 5. Chinese Companies 6. Summary and Forecast Companies Mentioned - Anhui Fulltime Specialized Solvent & Reagent - Danaher - Guangdong Guanghua Sci-Tech - Jianghua Microelectronics Materials - Jiangyin Chemical Reagent Factory - Johnson Matthey - Merck Group - Sigma-Aldrich - Sinopharm Group - Suzhou Crystal Clear Chemical - Suzhou JIMCEL Electronic New Material - TCI - Thermo Fisher - Wako - Xilong Chemical For more information visit http://www.researchandmarkets.com/research/sjcjmv/global_and
MRK: 57.95 (+0.57), DHR: 86.65 (+0.91)
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
BSPM: 1.01 (+0.03), BAX: 37.61 (+0.59), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), SVA: 5.26 (+0.02), SNY: 51.49 (+2.71), CPHI: 0.28 (-0.01)
Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, and Sinopharm A-THINK Pharmaceutical Co., Ltd.
Business Wire - Mon Aug 18, 8:19AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus"
, announced today that it entered into a Memorandum of Understanding ("MOU" with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI" , the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK" , the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group. PVCT: 0.51 (+0.01)
